Sugi Predict

Sugi Predict / Compounds / SCHEMBL129724

SCHEMBL129724

SCHEMBL129724

N#CC(C#N)=Cc1ccc(O)c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS4 Q9NRS4 12/20 0.65
▸ P2RX1 P51575 15/20 0.62
▸ P2RX7 Q99572 7/20 0.59
▸ P2RX4 Q99571 6/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ IKBKB O14920 1/20 0.59
▸ CHUK O15111 1/20 0.59
▸ KDR P35968 1/20 0.59
▸ FLT3 P36888 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MYLK Q15746 1/20 0.59
▸ MAP4K5 Q9Y4K4 1/20 0.59
▸ ERBB2 P04626 1/20 0.49
▸ SLC2A1 P11166 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330415 0.88 TMPRSS4 (0.61) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL330212 0.85 TMPRSS4 (0.58) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL134235 0.79 TMPRSS4 (1.00) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL130844 0.79 P2RX1 (0.66) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL130845 0.79 P2RX1 (0.66) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL130439 0.78 P2RX1 (0.81) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL23303456 0.77 P2RX1 (1.00) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL132386 0.76 P2RX1 (1.00) TMPRSS4P2RX1P2RX7P2RX4MEN1
Imd-0354 SCHEMBL129165 0.75 TMPRSS4 (1.00) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL130929 0.75 P2RX1 (0.74) TMPRSS4P2RX1P2RX7P2RX4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503425-B2 Methods of treating or controlling cytotoxic cerebral edema AEROMICS, INC. (US) 2025-12-23 — — US disclosed
US-20240360077-A1 METHODS AEROMICS, INC. 2024-10-31 — — US disclosed
US-11873266-B2 Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke AEROMICS, INC. (US) 2024-01-16 — — US disclosed
US-20220081391-A1 METHODS AEROMICS, INC. 2022-03-17 — — US disclosed
CN-109512805-B Compounds for the treatment of aquaporin mediated diseases 埃罗米克斯公司 2021-12-31 — — CN disclosed
US-11084778-B2 Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia AEROMICS, INC. (US) 2021-08-10 — — US disclosed
US-20180334424-A1 METHODS AEROMICS, INC. 2018-11-22 — — US disclosed
EP-2846787-B1 Compounds for use in the treatment of aquaporin-mediated diseases AEROMICS INC (US) 2018-08-29 — — EP disclosed
US-9994514-B2 Methods of treating cerebral edema and spinal cord edema AEROMICS, INC. (US) 2018-06-12 — — US disclosed
US-9949991-B2 Methods of treating aquaporin-mediated conditions AEROMICS, INC. (US) 2018-04-24 — — US disclosed
US-20060014811-A1 Medicament for treatment of cancer INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-01-19 — — US disclosed
EP-1555018-A1 REMEDIES FOR NEURODEGENERATIVE DISEASES Institute of Medicinal Molecular Design, Inc. (JP) 2005-07-20 — — EP disclosed
EP-1535610-A1 THERAPEUTIC AGENT FOR CANCER Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 — — EP disclosed
EP-1535609-A1 NF-KB ACTIVATION INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 — — EP disclosed
EP-1514544-A1 ANTIALLERGIC Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-16 — — EP disclosed
EP-1512396-A1 INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 — — EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 — — US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180334424-A1 METHODS AQP4, AQP1, AQP3 TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885
US-12503425-B2 Methods of treating or controlling cytotoxic cerebral edema AQP4, AQP1, AQP3 TMPRSS4 1043/4885P2RX1 2714/4885P2RX7 2687/4885
US-20220081391-A1 METHODS AQP4, AQP1, AQP3 TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885
US-20060014811-A1 Medicament for treatment of cancer HDAC3, HDAC1, HDAC6 TMPRSS4 3353/4885P2RX1 4850/4885P2RX7 4811/4885
US-11084778-B2 Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia AQP4, AQP1, AQP3 TMPRSS4 946/4885P2RX1 2805/4885P2RX7 2680/4885
US-11873266-B2 Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke AQP4, AQP1, AQP3 TMPRSS4 1444/4885P2RX1 3317/4885P2RX7 3316/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB TMPRSS4 3292/4885P2RX1 2316/4885P2RX7 1605/4885
US-20240360077-A1 METHODS AQP4, AQP1, AQP3 TMPRSS4 1415/4885P2RX1 2797/4885P2RX7 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.